Search results for: physical function

Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP | August 15, 2018

New research shows tanezumab may be safe and effective for patients with osteoarthritis pain…

Long-Term Apremilast Promising for Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP | July 27, 2018

In a long-term study, apremilast was well tolerated by patients with psoriatic arthritis, who showed sustained improvements for up to five years…

Pfizer-Lilly Pain Drug Meets Late-Stage Trial Goals

Manas Mishra | July 26, 2018

(Reuters)—An experimental osteoarthritis drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of lowering pain in a late stage trial, the companies said on Wednesday, potentially offering a safer alternative to opioids. Opioid abuse has reached epidemic proportions in the United States and drugmakers have been looking for less addictive…

Improve Your Recognition & Treatment of Osteoporosis

Jason Liebowitz, MD, FACR | July 19, 2018

BALTIMORE—Rheumatologists may not think about osteoporosis on a daily basis, but they should, said Dr. Karl Insogna, the Ensign Professor of Medicine at Yale University School of Medicine and director of the Yale Bone Center in New Haven, Conn., in his recent lecture at the Maryland Society for the Rheumatic Diseases. With approximately 75 million…

Study Finds Young Adults with Lupus at High Risk for Depression

Elizabeth Hofheinz, MPH, MEd | July 19, 2018

As if the fatigue, joint pain, etc., were not enough, new research has found many lupus patients must contend with clinical depression as well—something that can have a devastating cascade effect on other areas of their lives. Are adults with childhood-onset lupus at greater risk of depression than lupus patients with onset of disease during…

FDA Approves Baricitinib for RA Patients

Michele B. Kaufman, PharmD, BCGP | June 25, 2018

The FDA has approved baricitinib in a 2 mg tablet dose to treat patients with moderate to severe active rheumatoid arthritis…

Can Rheumatologists Get More Systematic about Psychosocial Care?

Larry Beresford | June 21, 2018

A recent position statement by the Society of Behavioral Medicine (SBM) concludes that patients with persistent pain need better access to psychosocial care in all healthcare settings.1 The SBM offers 10 health policy recommendations for improving such access, including removing system-related barriers, providing referral tools, reimbursing for evidence-based psychosocial approaches, prioritizing generalist-level and specialist pain…

FDA to Review Abuse-Deterrent Oxycodone Capsule

Michele B. Kaufman, PharmD, BCGP | May 18, 2018

FDA to Review Abuse-Deterrent Oxycodone Capsule In June, the FDA will discuss the New Drug Application for Remoxy ER at an Advisory Committee meeting. Remoxy ER is a 12-hour, abuse-deterrent, extended-release oxycodone in a capsule formulation.1 The capsule contains a sticky, thick, high-viscosity formulation to deter unapproved drug administration routes, including injection, smoking or snorting….

Rheumatology Can Use MACRA to Drive Healthcare Improvements

Terence W. Starz, MD, Theodore Pincus, MD, & Janet Bahr, NP, on behalf of the ARHP Practice Committee | May 18, 2018

We have entered the second year of the Medicare Access and CHIP (Children’s Health Insurance Program) Reauthorization Act (MACRA) of 2015. It’s no secret that the costs of medical care—17.1% of the U.S. gross national product compared with 9.8% in Great Britain, 10.7% in Canada and 11.6% in France—have become an overwhelming driver for change….

FDA Update: Committee Recommends 2 mg Baricitinib Approval; HLH Identified as Serious Adverse Event for Lamotrigine

Michele B. Kaufman, PharmD, BCGP | May 8, 2018

The FDA Arthritis Advisory Committee has recommended the approval of 2 mg baricitinib (but not in a 4 mg dose) for treating adults with moderate to severe active RA…